

Novartis in Nephrology

Building on Experience to Help Shape the Future

With a 40-year history in the transplant space, **Novartis** is reaching beyond its heritage to transform the lives of patients living with IgA nephropathy or C3G.^{1,2}

Innovating solutions for unmet needs

We are committed to addressing the current unmet needs for patients with CKD, IgA nephropathy, or C3G through investigating new options that may slow kidney disease progression and extend dialysis-free life.

We demonstrate this mission through:


- Partnerships with professional kidney organizations and societies, patient advocacy groups, and the nephrology community
- Continued clinical research with the nephrology community and our research facilities
- Establishing a long-term clinical pipeline in kidney diseases




“Seeing the research, seeing that people care about us, it means the world.”³

Kimberly
Patient with IgA nephropathy

Scan the QR codes or visit [GlomTalk.com](https://www.novartis.com/us-en/about/company-history)



IgA nephropathy



C3G

C3G, complement 3 glomerulopathy; CKD, chronic kidney disease; IgA, immunoglobulin A.

References: **1.** Drug that reduces risk in transplants gets early approval. News release. Associated Press; September 3, 1983. Accessed May 8, 2023. <https://www.nytimes.com/1983/09/03/us/drug-that-reduces-risk-in-transplants-gets-early-approval.html> **2.** Data on file. Company history. Novartis Pharmaceuticals Corp; May 2023. Accessed May 8, 2023. <https://www.novartis.com/us-en/about/company-history> **3.** Data on file. Rare renal digital ethnography, Novartis Pharmaceuticals Corp; October 2022.

